After twelve years, funding for the Collaborative Research Center (CRC) 1002 “Modulatory Units in Heart Failure”, which is based at the Heart Centre of the University Medical Center Göttingen (UMG), will end on 30 June 2024. New diagnostic and therapeutic approaches for the treatment of heart failure were developed and new insights into the development of the disease were gained. A high-calibre symposium with international speakers was held in Göttingen in May to mark the conclusion of CRC 1002.
The CRC 1002, headed by MBExC member Prof. Dr. Gerd Hasenfuß, was set up with the aim of better understanding the complex mechanisms of heart failure and developing innovative therapeutic approaches and received around 34 million euros from the German Research Foundation (DFG) over three funding periods. The researchers developed new treatment methods that are currently being tested in clinical trials. High-resolution imaging techniques and molecular biological methods were used to investigate signalling pathways that play a role in the development of heart failure.
Link to the DZHK press release
Link to the UMG press release (in German)
Prof. Dr. Gerd Hasenfuß, Director of the Department of Cardiology and Pneumology and Chairman of the Heart Center of the University Medical Center Göttingen (UMG) and spokesperson for the Collaborative Research Center (CRC) 1002. Photo: Pförtner/ MBExC
